Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Rhea-AI Summary

Pasithea Therapeutics (NASDAQ: KTTA) will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, at the InterContinental Boston.

The clinical-stage biotech, developing PAS-004 for chronic diseases including NF1-related neurocutaneous manifestations, will hold one-on-one investor meetings and join event discussions.

News Market Reaction – KTTA

-1.60%

2 alerts

-1.60% News Effect

+10.9% Peak Tracked

-$282K Valuation Impact

$17.37M Market Cap

7.06K Volume

On the day this news was published, KTTA declined 1.60%, reflecting a mild negative market reaction. Argus tracked a peak move of +10.9% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $282K from the company's valuation, bringing the market cap to $17.37M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Pasithea’s planned presence at the Mind, Muscle & Vision Summit on July 16, 2026 reinforces its neur...

Analysis

Pasithea’s planned presence at the Mind, Muscle & Vision Summit on July 16, 2026 reinforces its neurology-focused profile. Investors may contextualize this with recent clinical news flow and ongoing financing needs highlighted in prior SEC filings.

Key Figures

Conference date: July 16, 2026

1 metrics

Conference date July 16, 2026 Mind, Muscle & Vision Summit participation

Historical Context

5 past events · Latest: Jun 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 30	Phase 1 data update	Positive	-2.0%	Interim Phase 1 PAS-004 data showed long-term safety and durable activity.
Jun 16	Protocol amendment	Positive	-8.9%	NF1 trial protocol expanded dosing, duration and imaging ahead of data update.
Jun 15	Conference participation	Positive	-5.3%	Exhibit at 2026 NF Conference following recent FDA designations for PAS-004.
Jun 02	Orphan designation	Positive	-9.8%	FDA granted Orphan Drug Designation for PAS-004 in ALS treatment.
May 04	CMO appointment	Positive	+0.7%	Industry veteran appointed CMO to lead PAS-004 clinical development strategy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent KTTA news, including positive clinical and designation updates, has often been followed by short-term share price declines.

Key Terms

mek inhibitor, neurofibromatosis type 1, neuroimmunology, neurodegeneration, +2 more

6 terms

mek inhibitor medical

"developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term"

A MEK inhibitor is a drug that blocks MEK enzymes, which act like a relay in a cell’s growth-signaling pathway; by cutting that relay these drugs can slow or stop uncontrolled cell growth seen in some cancers and other proliferative conditions. Investors care because clinical trial outcomes, safety data, and regulatory approvals determine whether a MEK inhibitor becomes a marketable therapy, directly affecting a developer’s revenue prospects and valuation — like a product passing a crucial safety and sales test.

neurofibromatosis type 1 medical

"chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1)"

A genetic condition that causes noncancerous tumors to grow on nerves and can lead to skin changes, pain, learning challenges and other complications; severity varies widely from mild to serious. Investors track it because treatments, diagnostics and care pathways for this distinct patient group can drive clinical trial outcomes, regulatory approvals and long‑term revenue, much like a niche market where the size, unmet need and treatment complexity determine potential returns.

neuroimmunology medical

"covering neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology, and neuroimmunology"

The study of how the immune system and the nervous system interact, including how immune activity affects brain and nerve function and how nerves influence immune responses. Imagine two teams that usually work separately learning to talk to each other; understanding that conversation can reveal causes of diseases, new drug targets, and biomarkers. That matters to investors because discoveries in this field can change the outlook for drug development, clinical trial results, regulatory review, and potential market opportunities in neurological and immune-related conditions.

neurodegeneration medical

"event covering neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology"

Neurodegeneration is the gradual damage and loss of nerve cells in the brain and nervous system, producing symptoms such as memory decline, impaired movement, or thinking problems. Think of it like electrical wiring in a house slowly fraying, which undermines how the system runs. For investors it matters because it drives demand for diagnostics, treatments and long-term care, influences regulatory risk and trial outcomes, and can significantly affect the value of health-care and biotech companies.

neuropsychiatry medical

"event covering neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology"

A medical specialty that studies and treats conditions where brain structure or function leads to mental and behavioral symptoms, acting as a bridge between neurology (the brain’s wiring) and psychiatry (mood, thinking and behavior). For investors, neuropsychiatry matters because it drives development of drugs, diagnostics and devices targeting brain-linked mental disorders, influencing regulatory hurdles, market size and the pace at which new treatments can reach patients — like assessing both the engine and the control system of a car.

neuromuscular medical

"neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases"

Relating to the connection and interaction between nerves and muscles, neuromuscular describes how signals from the nervous system make muscles move and function. For investors, neuromuscular issues and treatments matter because they drive demand for drugs, devices and diagnostic tests, shape development timelines and regulatory risks, and can change long-term revenue prospects in healthcare—think of it like the wiring and motors in a machine where problems or fixes affect overall performance and value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

July 16 in Boston, management will engage with investors and industry participants at the healthcare-focused event covering neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology, and neuroimmunology

MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle & Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.

The Mind, Muscle & Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. The event will feature one-on-one investor meetings, panel discussions and fireside chats.

Pasithea management will be available for one-on-one meetings with institutional investors and other conference participants throughout the event.

For additional information regarding the conference or to schedule a meeting with Pasithea management, interested parties should contact their B. Riley Securities representative.

About Pasithea Therapeutics Corp.

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in patients with advanced cancer (NCT06299839), and a Phase 1/1b clinical trial in patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas with symptomatic and inoperable, incompletely resected, or recurrent PN (NCT06961565).

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Pasithea Therapeutics Contact

Patrick Gaynes
Investor Relations
pgaynes@pasithea.com

FAQ

What is Pasithea Therapeutics (NASDAQ: KTTA) announcing about the Mind, Muscle & Vision Summit?

Pasithea Therapeutics is announcing its participation in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston. According to Pasithea, management will engage in one-on-one investor meetings, panel discussions, and fireside chats across key neurological therapeutic areas.

When and where will Pasithea Therapeutics present at the B. Riley Mind, Muscle & Vision Summit 2026?

Pasithea Therapeutics will participate in the Mind, Muscle & Vision Summit on July 16, 2026, at the InterContinental Boston in Massachusetts. According to Pasithea, the summit is a healthcare-focused event bringing together companies in neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology, and neuroimmunology.

What is Pasithea Therapeutics’ focus and lead program PAS-004 mentioned in the July 2026 summit news?

Pasithea Therapeutics is a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor. According to Pasithea, PAS-004 targets long-term treatment of chronic diseases, including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), aligning with the summit’s neurology-focused themes.

How can investors schedule one-on-one meetings with Pasithea Therapeutics (KTTA) at the Mind, Muscle & Vision Summit?

Institutional investors can schedule one-on-one meetings with Pasithea management through their B. Riley Securities representative. According to Pasithea, management will be available for meetings throughout the summit, offering investors direct engagement on the company’s clinical programs and strategy.

What therapeutic areas will be highlighted at the B. Riley Mind, Muscle & Vision Summit featuring Pasithea Therapeutics?

The summit will highlight neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology, and neuroimmunology. According to Pasithea, the event brings together leading biotechnology and pharmaceutical companies active in these neurological and vision-related fields, providing a forum for discussion and investor interaction.

Why is Pasithea Therapeutics’ participation in the July 16, 2026 Mind, Muscle & Vision Summit important for KTTA investors?

Participation offers KTTA investors enhanced access to management and visibility among specialized healthcare investors. According to Pasithea, one-on-one meetings and panel involvement may help communicate progress on PAS-004 and the company’s broader clinical strategy to the investment community.